This treatment has the potential to offer a new therapeutic option for patients who continue to suffer partial seizures despite receiving other anti-epileptic agents, with the potential for additional benefits in terms of improvements in quality of life and depressive symptoms.(2,3,4,5,6,7)
Founded in 1924, BIAL is an international pharmaceuticals group with products available in nearly 30 countries over four continents. BIAL group is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal.
BIAL is strongly committed to therapeutic innovation on research and development every year. This commitment has been recognised in the group's recent integration into the EFPIA (European Federation of Pharmaceutical Industries and Associations), which is dedicated to encouraging research and the development of new therapeutic options.
Key research areas for BIAL are the central nervous system, the cardiovascular system and allergology. BIAL's dedication to research is further demonstrated by the research grants and awards offered by the BIAL Foundation.
Further information about BIAL can be found at http://www.bial.com
(1). Zebinix(TM) is one of the proposed EU trade names for Eslicarbazepine acetate
(2). Elger C, Halasz P, Maia J et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.
(3). Hufnagel A, Ben-Menachem E, Gabbai A et al. Efficacy and safety of
eslicarbazepine acetate as add-on treatment in adults with refractory
partial-onset seizures: BIA
Copyright©2008 PR Newswire.
All rights reserved